《新英格兰医学杂志》STEP Young三期试验11月16日公布:167名6至12岁肥胖儿童68周BMI降17.4%,安慰剂组升2.2%

诺和诺德11月16日公布三期试验 STEP Young 的主要结果,试验在 ObesityWeek 2026 学术研讨会上报告,并同步发表于《新英格兰医学杂志》。试验评估每周一次司美格鲁肽注射联合低热量饮食与增加身体活动,用于6至12岁以下肥胖儿童。
试验为随机、双盲、安慰剂对照的多国研究,共入组167名儿童,司美格鲁肽组112人、安慰剂组55人,最大剂量按基线体重定为1.7毫克或2.4毫克。入组儿童中逾85%在基线时属II级或III级重度肥胖。
按疗效估计目标,第68周时司美格鲁肽组 BMI 平均百分比变化为 −17.4%,安慰剂组为 +2.2%,估计治疗差异为 −19.7个百分点。司美格鲁肽组78.7%的儿童 BMI 降幅达到10%或以上,安慰剂组为0%;83.0%的司美格鲁肽组儿童 BMI 类别得到改善,安慰剂组为23.5%;40.4%的司美格鲁肽组儿童不再被归类为肥胖,安慰剂组为0%。
公司表示,试验中司美格鲁肽的安全性与耐受性与既往儿童与成人试验一致,未发现新的安全问题,也未发现对生长或青春期发育的安全担忧。司美格鲁肽注射液目前未获美国批准用于12岁以下儿童,其在该人群的安全性与有效性尚未确立。
图中是司美格鲁肽与受体结合的结构模型,STEP Young 试验评估的正是每周一次的司美格鲁肽注射。
STEP Young Phase 3 Trial in The New England Journal of Medicine, Announced November 16: BMI Fell 17.4% at Week 68 in 167 Children Aged 6 to Under 12, Versus a 2.2% Rise on Placebo
Novo Nordisk announced the primary results of the Phase 3 STEP Young trial on November 16; the results were presented at a scientific symposium at ObesityWeek 2026 and simultaneously published in The New England Journal of Medicine. The trial evaluated once-weekly semaglutide injection, combined with a reduced-calorie diet and increased physical activity, in children aged 6 to under 12 years with obesity.
STEP Young was a randomized, double-blind, placebo-controlled multinational trial enrolling 167 children, 112 on semaglutide and 55 on placebo, with a maximum dose of 1.7 mg or 2.4 mg set by baseline body weight. More than 85% of the children had class II or III severe obesity at baseline.
At week 68, on the efficacy estimand, the estimated mean percentage change in BMI was −17.4% with semaglutide and +2.2% with placebo, an estimated treatment difference of −19.7 percentage points. A BMI reduction of 10% or more was observed in 78.7% of semaglutide-treated children versus 0% on placebo; 83.0% of the semaglutide group improved their BMI category, versus 23.5% on placebo; and 40.4% of semaglutide-treated children were no longer classified as having obesity, versus 0% on placebo.
The company said the safety and tolerability profile was consistent with previous pediatric and adult semaglutide trials, with no unexpected safety concerns and no safety concerns identified for growth or pubertal development. Semaglutide injection is not approved in the United States for children under 12, and its safety and efficacy in that population are not established.
发布:GSM·美国(发布链接)
图片来源:Wikimedia Commons, File:Semaglutide PDB=7ki0.png — Deposition authors: Zhang, X., Belousoff, M.J., Danev, R., Sexton, P.M., Wootten, D. et al. Licensing: CC0.
GSM Global · 本篇英文版 English edition of this story

